|
CRAMP1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.0295997387999E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.25295346215171E-14 |
| Normal-vs-Stage2 |
9.77370000487809E-08 |
| Normal-vs-Stage3 |
1.38777878078145E-13 |
| Normal-vs-Stage4 |
6.88590295894187E-11 |
| Stage1-vs-Stage2 |
9.754000E-01 |
| Stage1-vs-Stage3 |
7.965800E-02 |
| Stage1-vs-Stage4 |
1.099020E-01 |
| Stage2-vs-Stage3 |
2.491800E-01 |
| Stage2-vs-Stage4 |
2.059800E-01 |
| Stage3-vs-Stage4 |
8.164800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.74460002000387E-10 |
| Normal-vs-AfricanAmerican |
6.38600000000267E-05 |
| Normal-vs-Asian |
1.40829999994985E-07 |
| Caucasian-vs-AfricanAmerican |
6.634000E-01 |
| Caucasian-vs-Asian |
4.766000E-01 |
| AfricanAmerican-vs-Asian |
9.368400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.37201402753362E-12 |
| Normal-vs-Female |
9.8637986667427E-11 |
| Male-vs-Female |
8.321600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.76759989662423E-10 |
| Normal-vs-Age(41-60Yrs) |
6.72906175225307E-13 |
| Normal-vs-Age(61-80Yrs) |
3.73799879938019E-11 |
| Normal-vs-Age(81-100Yrs) |
1.644640E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.766600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.782440E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.853400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.981800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.796600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.140600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.70119999998164E-06 |
| Classical-VS-Follicular |
1.344640E-01 |
| Classical-VS-Other |
4.980800E-01 |
| Classical-VS-Normal |
6.02179994757535E-09 |
| Tall-VS-Follicular |
1.395700E-02 |
| Tall-VS-Other |
3.748200E-01 |
| Tall-VS-Normal |
6.90558721316847E-14 |
| Follicular-VS-Other |
9.264000E-01 |
| Follicular-VS-Normal |
1.46999967753914E-10 |
| Other-VS-Normal |
3.617400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.20459198171829E-13 |
| Normal-vs-N1 |
1.14450005028743E-09 |
| N0-vs-N1 |
5.379200E-01 |
|
|
